In the past week, HALO stock has gone down by -9.54%, with a monthly gain of 0.94% and a quarterly plunge of -9.19%. The volatility ratio for the week is 5.02%, and the volatility levels for the last 30 days are 3.66% for Halozyme Therapeutics Inc The simple moving average for the past 20 days is -1.57% for HALO’s stock, with a 10.21% simple moving average for the past 200 days.
Is It Worth Investing in Halozyme Therapeutics Inc (NASDAQ: HALO) Right Now?
Halozyme Therapeutics Inc (NASDAQ: HALO) has a higher price-to-earnings ratio of 17.86x compared to its average ratio. HALO has 36-month beta value of 1.28. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HALO is 125.85M, and currently, short sellers hold a 8.14% ratio of that float. The average trading volume of HALO on November 15, 2024 was 1.38M shares.
HALO) stock’s latest price update
Halozyme Therapeutics Inc (NASDAQ: HALO)’s stock price has decreased by -7.93 compared to its previous closing price of 58.61. However, the company has seen a -9.54% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-14 that Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO, Nov. 14, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) (“Evotec”) to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec’s undisturbed share price on October 15, 2024, the day prior to Triton Partners’ initial accumulation of Evotec shares, and a premium of 77% to Evotec’s last three-month volume weighted average price on October 15, 2024.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Wells Fargo repeating the rating for HALO by listing it as a “Equal Weight.” The predicted price for HALO in the upcoming period, according to Wells Fargo is $62 based on the research report published on October 07, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see HALO reach a price target of $57, previously predicting the price at $52. The rating they have provided for HALO stocks is “Neutral” according to the report published on September 19th, 2024.
Piper Sandler gave a rating of “Neutral” to HALO, setting the target price at $51 in the report published on June 07th of the current year.
HALO Trading at -4.18% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.66% of loss for the given period.
Volatility was left at 3.66%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares surge +3.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.61% lower at present.
During the last 5 trading sessions, HALO fell by -9.54%, which changed the moving average for the period of 200-days by +59.41% in comparison to the 20-day moving average, which settled at $54.82. In addition, Halozyme Therapeutics Inc saw 46.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from LaBarre Michael J., who sale 10,000 shares at the price of $53.75 back on Oct 15 ’24. After this action, LaBarre Michael J. now owns 173,756 shares of Halozyme Therapeutics Inc, valued at $537,469 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc, sale 10,000 shares at $53.26 during a trade that took place back on Oct 16 ’24, which means that LaBarre Michael J. is holding 173,756 shares at $532,590 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.5 for the present operating margin
- 0.78 for the gross margin
The net margin for Halozyme Therapeutics Inc stands at 0.41. The total capital return value is set at 0.24. Equity return is now at value 111.83, with 19.57 for asset returns.
Based on Halozyme Therapeutics Inc (HALO), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 3.32. The interest coverage ratio of the stock is 49.04.
Currently, EBITDA for the company is 451.95 million with net debt to EBITDA at 2.37. When we switch over and look at the enterprise to sales, we see a ratio of 8.67. The receivables turnover for the company is 3.32for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.36.
Conclusion
To put it simply, Halozyme Therapeutics Inc (HALO) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
